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responsibility of XAbstract A stability-indicating RP-HPLC method was developed and validated for the determi-
nation of Ruﬁnamide in tablet dosage forms using C 18 column (250 mm 4.6 mm, 5 mm) with
mobile phase consisting of water–acetonitrile (40:60, v/v) with a ﬂow rate of 0.8 mL/min (UV
detection 215 nm). Linearity was observed over the concentration range 1.0–200 mg/mL (R2¼0.9997)
with regression equation y¼113190 xþ63053. Ruﬁnamide was subjected to stress conditions including
acidic, alkaline, oxidation, photolysis and thermal degradation. Ruﬁnamide is more sensitive towards
acidic degradation. The method was validated as per ICH guidelines.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Ruﬁnamide is an antiepileptic drug approved by the US Food and
Drug Administration as an adjunctive treatment of seizures
associated with Lennox–Gastaut syndrome in children 4 years
and older and adults. Lennox–Gastaut syndrome consists of a
variety of treatment-resistant seizures and is most common among
pediatric patients [1]. Ruﬁnamide is chemically known as 1-[(2, 6-
diﬂuorophenyl) methyl]-1 H-1,2,3-triazole-4 carboxamide (Fig. 1).ersity. Production and hosting by E
.003
5143573;
com (B. Sai Pavan Kumar).
i’an Jiaotong University.The mechanism of action of Ruﬁnamide involves stabilization of
the sodium channel inactive state, effectively keeping the ion
channels closed. It is believed to prolong the refractory period of
voltage-dependent sodium channels, making neurons less likely to
ﬁre [2]. To date, all analytical methods described in literature for
the determination of Ruﬁnamide in biological ﬂuids involve liquid
chromatography [3–7], liquid chromatography–mass spectrometry
[8] and HPLC [9] methods. In the present work, we developed a
simple, precise, accurate, selective and robust liquid chromato-
graphic method for the determination of Ruﬁnamide in pharma-
ceutical dosage form as an alternative method.
2. Experimental
2.1. Chemicals and reagents
Ruﬁnamide standard (purityZ98.0%) was obtained from Eisai
Pharmaceuticals (Visakhapatnam, India). Acetonitrile (HPLClsevier B.V. All rights reserved.
Stability-indicating RP-HPLC method for the determination of Ruﬁnamide 67grade), sodium hydroxide, hydrochloric acid and hydrogen
peroxide were purchased from Merck (India). Ruﬁnamide is
available as tablets with brand names PrBANZELTMs and
BANZELs with label claim of 100, 200 and 400 mg of drug.
All chemicals were of analytical grade and used as received.Fig. 1 Chemical structure of Ruﬁnamide.
Table 1 Comparison of the performance characteristics of the p
S.
no.
Method/reagent l
(nm)
Linear
(mg/m
1. HPLC (Robotic system) 230 0.05–4
2. HPLC/acetonitrile: methanol: potassium
dihydrogen phosphate
– 0.05–1
3 HPLC/acetonitrile: methanol: potassium
dihydrogen phosphate
– 0.05–2
4 HPLC/acetonitrile: methanol potassium
dihydrogen phosphate buffer (pH 4.5)
210 2–4
5 HPLC/methanol: dichloromethane:n-hexane 230 0.25–2
6 LC–MS – 0.48–4
7 HPLC/methanol: water (pH 3.0) 220 10–6
8 HPLC/acetonitrile: water (60:40, v/v) 215 1.0–20
Fig. 2 Representative chromatograms of Ruﬁnamide (50 mg/mL) (A2.2. HPLC instrumentation and conditions
Chromatographic separation was achieved by using a Shimadzu
Model CBM-20 A/20 Alite HPLC system, equipped with an
SPD M20A prominence photodiode array detector
(250 mm 4.6 mm, 5 mm particle size) maintained at 25 1C.
Isocratic elution was performed using acetonitrile and water
(60:40, v/v) with ﬂow rate 0.8 mL/min. 20 mL of sample was
injected into the HPLC system.
Ruﬁnamide stock solution (1000 mg/mL) was prepared by
accurately weighing 25 mg of Ruﬁnamide in a 25 mL amber
volumetric ﬂask and making up to volume with mobile phase.
Working solutions for HPLC injections were prepared on a daily
basis from the stock solution in a solvent mixture of acetonitrile
and water (60:40, v/v) (mobile phase). Solutions were ﬁltered
through a 0.45 mm membrane ﬁlter prior to injection.
20 tablets from each brand (PrBANZELTMs and BANZELs)
were procured, weighed and crushed to a ﬁne powder. Powder
equivalent to 25 mg Ruﬁnamide was accurately weighed into aresent method with the published methods.
ity
L)
Remarks Ref.
.0 Human plasma [3]
9.09 Plasma (liquid-solid extraction) [4]
0 Plasma and brain [5]
0 Very narrow linearity range (UV/visible
detector)
[6]
0.0 Plasma and saliva [7]
7.6 Dried blood spots [8]
0 Very narrow linearity range [9]
0 Wide linearity range stability indicating
method (PDA detector)
Present work
), PrBANZELTMs (400 mg) (B), and BANZELs (400 mg) (C).
B. Sai Pavan Kumar et al.6825 mL volumetric ﬂask and made up to volume with mobile
phase. The contents of the volumetric ﬂask were sonicated for
30 min to enable complete dissolution of Ruﬁnamide. The
solution was ﬁltered and the ﬁltrate was diluted with mobile
phase. 20 mL of these solutions were injected into the system and
the peak area was recorded from the respective chromatogram.
2.3. Method validation
The method was validated for the following parameters:
linearity, precision, accuracy, selectivity, robustness, limit of
quantitation (LOQ), limit of detection (LOD) and system
suitability [11].
Linearity test solutions for the assay method were prepared
from a stock solution at different concentration levels and
20 mL of each solution was injected into the HPLC system and
the peak area of the chromatogram obtained was noted.
The intra-day precision of the assay method was evaluated
at three concentration levels (10, 20 and 50 mg/mL) (n¼3)
against a qualiﬁed reference standard. The inter-day precision
study was performed on three different days i.e. day 1, day 2
and day 3 at three different concentration levels (10, 20 and
50 mg/mL) (n¼3). The %RSD of the obtained assay values at
three different concentration levels was calculated.
The accuracy of the assay method was evaluated in
triplicate at three concentration levels (80, 100 and 120%),
and the percentage recoveries were calculated. The study was
carried out in triplicate at 18, 20 and 22 mg/mL.
The robustness of the assay method was established by
introducing small changes in the HPLC conditions which
included wavelength (213 and 217 nm), percentage of acet-
onitirile in the mobile phase (58 and 62) and ﬂow rate (0.7 andTable 2 Linearity of Ruﬁnamide.
Conc. (mg/mL) Mean peak
area 7SD (n¼3)
RSD (%)
1 1169227379 0.32
5 58251071648 0.28
10 117419075836 0.50
20 226269777354 0.33
50 5858816716053 0.27
100 11678667716584 0.14
150 17018877755822 0.33
200 22544511751176 0.23
nMean of three replicates.
Table 3 Intra-day and inter-day precision studies of Ruﬁnamide
Sample no. Conc. (mg/mL) Intra-day precision
Mean peak area 7SD
1 10 117332171678
2 20 225636476506
3 50 5846397713619
nMean of three replicates.0.9 mL/min). Robustness of the method was studied using six
replicates at a concentration level of 20 mg/mL of Ruﬁnamide.
The LOQ and LOD were based on the standard deviation
of the response and the slope of the constructed calibration
curve (n¼3), as described in International Conference on
Harmonization guidelines Q2 (R1) [11].
The solutions extracted from the marketed formulations
were also injected into the HPLC system and the peak area of
the chromatograms was noted. A calibration curve was
plotted by taking concentration of the drug solution on the
x-axis and the corresponding peak area on the y-axis.
2.4. Forced degradation studies/speciﬁcity
The study was intended to ensure the effective separation of
Ruﬁnamide and its degradation peaks of formulation ingre-
dients at the retention time of Ruﬁnamide. Forced degrada-
tion studies were performed to evaluate the stability indicating
properties and speciﬁcity of the method [10].
All solutions for use in stress studies were prepared at an
initial concentration of 1 mg/mL of Ruﬁnamide and reﬂuxed
for 30 min at 80 1C. All samples were then diluted in mobile
phase to give a ﬁnal concentration of 50 mg/mL and ﬁltered
before injection.
Acid decomposition was carried out in 0.1 M HCl and
alkaline degradation was conducted using 0.1 M NaOH and
reﬂuxed for 30 min at 80 1C. After cooling the solutions were
neutralized and diluted with mobile phase.
Solutions for oxidative stress studies were prepared using
3% H2O2 at a concentration of 1 mg/mL of Ruﬁnamide and
after reﬂuxation for 30 min at 80 1C on the thermostat the
sample solution was cooled and diluted accordingly with the
mobile phase.
For thermal stress testing, the drug solution (1 mg/mL) was
heated in thermostat at 80 1C for 30 min, cooled and used. The
drug solution (1 mg/mL) for photo stability testing was exposed
to UV light for 4 h UV light chamber (365 nm) and analyzed.3. Results and discussion
No stability indicating method is available in the ofﬁcial
compendia using HPLC for analyzing Ruﬁnamide in dosage
forms till now. The present proposed method was compared
with the reported methods in the literature and shown in
Table 1. The complete separation of the analytes was accom-
plished in less than 10 min and the method can be successfully
applicable to perform long-term and accelerate stability
studies of Ruﬁnamide formulations..
Inter-day precision
RSD (%) Mean peak area 7SD RSD (%)
0.14 117376979001 0.76
0.29 2264158713503 0.59
0.23 5832216735964 0.62
Stability-indicating RP-HPLC method for the determination of Ruﬁnamide 69Initially the stressed samples were analyzed using a mobile
phase consisting of water: acetonitrile (70:30, v/v) at a ﬂow rate
of 1.0 mL/min. Under these conditions, the resolution and peak
symmetry were not satisfactory, so the mobile phase wasTable 4 Accuracy–recovery study of Ruﬁnamide by standard-ad
Sample no. Spiked concentration (mg/mL) Measured c
1 8 (80%) 7.83
2 10 (100%) 9.87
3 12 (120%) 11.91
nMean of three replicates.
Table 5 Analysis of Ruﬁnamide commercial formulation (tablet
Sample no. Formulation Labeled claim (m
1 PrBANZELTMs 400
2 BANZELs 400
nMean of three replicates.
Table 6 Forced degradation studies of Ruﬁnamide.
Stress conditions Drug recover
Standard drug 100.00
Acidic hydrolysis 92.21
Alkaline hydrolysis 97.16
Oxidative degradation 94.36
Thermal degradation 99.96
Photolytic degradation 99.86
nMean of three replicates.
Fig. 3 Representative chromatograms of Ruﬁnamide (50 mg/mL) on
(E) degradations.changed to water: acetonitrile (40:60, v/v) with a ﬂow rate of
0.8 mL/min under which peaks were well resolved with good
symmetry and sharpness and therefore mobile phase containing
water: acetonitrile (40:60, v/v) was chosen for the entire study.dition method.
oncentration (mg/mL) Recovery (%) RSD (%)
97.87 0.71
98.70
99.25
s).
g) Amount found (mg) Recovery (%)
388.92 97.23
387.92 96.98
ed (%) Drug decomposed (%)
100.00
7.79
2.84
5.63
0.04
0.14
acidic (A), alkaline (B), oxidative (C), photolytic (D) and thermal
B. Sai Pavan Kumar et al.70The representative chromatogram obtained for Ruﬁnamide
is shown in Fig. 2A and those of marketed formulations are
shown in Fig. 2B–C. The calibration curve was linear over the
concentration range 1–200 mg/mL (Table 2) and the regression
equation was found to be y¼113190 xþ63053 with correlation
coefﬁcient of 0.9997.
The RSD in precision studies was found to be 0.14–0.29%
(Intra-day) and 0.59–0.76% (Inter-day) (Table 3). The % RSD
in accuracy studies (Table 4) and robustness studies was found
to be less than 2.0%, indicating that the method is precise,
accurate and robust. The LOQ was found to be 0.7346 mg/mL
and the LOD was found to be 0.2423 mg/mL.
The proposed method was applied for the determination of
Ruﬁnamide tablets and the results of these assays yielded
97.23–96.98%, respectively, with RSDo2.0% (Table 5).
The capacity factor was more than 2, theoretical plates were
8576 (more than 2000) and tailing factor was 1.26 (less than 2)
for the Ruﬁnamide peak. The % RSD value of assay
determined under original conditions and robustness condi-
tions was less than 2.0%, indicating that the developed
method was robust.
During the acidic degradation, 7.79% of the drug was
decomposed. The triazole and carboxamide groups present in
the Ruﬁnamide chemical structure may be responsible for the
reported acidic degradation. During the alkaline degradation a
major degradant was observed at 2.987 mins without interfer-
ing the elution of drug peak (3.891 mins) and the percentage of
drug decomposition was found to be 2.84%. Ruﬁnamide has
undergone thermal, oxidation and UV degradation slightly i.e
less than 6.0% (Table 6). Typical chromatograms obtained
following the assay of stressed samples are shown in Fig. 3.Acknowledgments
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